Skip to main content
SpringerLink
Log in

Making DOTS-Plus work

  • Chapter
Book cover Multidrug-resistant Tuberculosis

Part of the book series: Resurgent and Emerging Infectious Diseases ((REID,volume 1))

Abstract

The persistent generation and transmission of strains of Mycobacterium tuberculosis resistant to the first-line antituberculosis agents have been documented in a large number of settings [1]. In these regions, effective strategies for both the prevention and the treatment of drug-resistant tuberculosis (TB) are required, and delays in their implementation will likely prove costly. Such a strategy must successfully prevent further transmission of new infections through rendering individual patients first, non-infectious, and eventually, cured. Indeed, MDRTB control can only be achieved when all the sources currently fuelling this quietly advancing epidemic are quelled. A central tenet of modern TB control is that treatment is prevention [2]. As with drug-susceptible TB, effective therapy for infectious cases is the only acceptable strategy to curtail further spread of drug-resistant strains of M. tuberculosis, and the only likely way to defuse what some have termed a “time-bomb” [3,4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997 (WHO/TB/97.229). World Health Organization, Geneva, 1997.

    Google Scholar 

  2. Crofton J. The contribution of treatment to the prevention of tuberculosis. Bull Int Union Against Tuber 1962; 32: 643–653.

    Google Scholar 

  3. Iseman MD. Tailoring a time bomb: inadvertent genetic engineering. Am Rev Respir Dis 1985; 132: 735–736.

    PubMed  CAS  Google Scholar 

  4. Farmer PE, Bayona J, Becerra M, et al. The dilemma of MDRTB in the global era. Int J Tuberc Lung Dis 1998; 2: 869–876.

    PubMed  CAS  Google Scholar 

  5. Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990; 142: 1301–1305.

    PubMed  CAS  Google Scholar 

  6. Espinal MA, Kim SJ, Hong YP. Treatment outcome of multidrug resistant (MDR) tuberculosis (TB) cases under programme conditions. Int J Tuberc Lung Dis 1998; 2(Suppl.2): S371.

    Google Scholar 

  7. Farmer PE, Kim JY. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing “DOTS-plus”. BMJ 1998; 317: 671–674.

    Article  PubMed  CAS  Google Scholar 

  8. Farmer PE, Timperi R, Mitnick C, Kim JY. Responding to outbreaks of MDRTB: Introducing “DOTS-Plus”. In: Reichman LB, Hershfield ES (eds.), Tuberculosis: a comprehensive international approach, p. 447–469. Second edition. Marcel Dekker Inc., New York, 1999.

    Google Scholar 

  9. World Health Organization. Coordination of DOTS-Plus pilot projects for the management of MDR-TB (WHO/CDS/CBC/TB/99.262). World Health Organization, Geneva, 1999.

    Google Scholar 

  10. World Health Organization. Report: Basis for the development of an evidence-based case-management strategy for MDR TB within the WHO’s DOTS strategy (WHO/TB/99.260). World Health Organization, Geneva, 1999.

    Google Scholar 

  11. Farmer PE, Furin J, Bayona J, et al. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis 1999; 3: 643–645.

    PubMed  CAS  Google Scholar 

  12. Crofton J, Chaulet P, Maher D. Guidelines on the management of drug-resistant tuberculosis (WHO/TB/96.210). World Health Organization, Geneva, 1996.

    Google Scholar 

  13. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784–791.

    Article  PubMed  CAS  Google Scholar 

  14. Frieden TR, Sherman LF, Maw KL. A multi-institutional outbreak of highly drugresistant tuberculosis-epidemiology and clinical outcomes. JAMA 1996; 276: 1229–1235.

    Article  PubMed  CAS  Google Scholar 

  15. Ministerio de Salud. Tuberculosis en el Peru-Informe 1996. Ministerio de Salud, Lima, Peru, 1997.

    Google Scholar 

  16. Weyer K, Fourie PB, Nardell EA. Multidrug-resistant tuberculosis in South Africa. In: The Global Impact of Drug-Resistant Tuberculosis. Program in Infectious Disease and Social Change, Harvard Medical School Boston, MA, 1999.

    Google Scholar 

  17. World Health Organization. WHO Tuberculosis Programme: framework for effective tuberculosis control (WHO/TB/94.175). World Health Organization, Geneva, 1994.

    Google Scholar 

  18. Frieden TR, Fujiwara E, Washko R, Hamburg M. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333: 229–233.

    Article  PubMed  CAS  Google Scholar 

  19. Garrett L. The coming plague. Farrar, Straus, and Giroux, New York, 1994.

    Google Scholar 

  20. Farmer PE, Bayona J, Becerra M, et al. Poverty, inequality, and drug resistance: meeting community needs, p. 88-102. In: Proceedings of the International Union Against Tuberculosis and Lung Disease North American Region Conference, Feb. 27-Mar. 2, 1997.

    Google Scholar 

  21. Coninx R, Eshaya-Chauvin B, Reyes H. Tuberculosis in prisons. Lancet 1995; 346: 1238–1239.

    Article  PubMed  CAS  Google Scholar 

  22. Farmer PE. Cruel and unusual: drug-resistant tuberculosis as punishment. In: Stern V, Jones R (eds.), Sentenced to Die? The problem of TB in prisons in East and Central Europe and Central Asia. London, Penal Reform International, 1999.

    Google Scholar 

  23. Reyes H, Coninx R. Pitfalls of tuberculosis programmes in prisons. BMJ 1997; 315: 1447–1450.

    Article  PubMed  CAS  Google Scholar 

  24. Akin M. Soros gives $12M for fight against TB in prisons. The Moscow Times March 20, 1999.

    Google Scholar 

  25. Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999; 3: 582–588.

    PubMed  CAS  Google Scholar 

  26. Drobniewski F. Tuberculosis in prisons-forgotten plague. Lancet 1995; 346: 948–949.

    Article  PubMed  CAS  Google Scholar 

  27. Banatvala N, Matic S, Kimerling M, et al.. Tuberculosis in Russia. Lancet 1999; 354: 1036.

    Article  Google Scholar 

  28. Goldfarb A, Kimerling ME. PHRI/Soros Russian TB program: an initiative of the International Center for Public Health. Submitted to the Gore-Primakov Commission edition. New York, NY: Public Health Research Institute, March 23, 1999.

    Google Scholar 

  29. Goldfarb A, Healing T, Kimerling ME. PHRI/MERLIN/WHO Tomsk TB project. New York, NY: Public Health Research Institute, July 5, 1999.

    Google Scholar 

  30. Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drugresistant Mycobacterium tuberculosis in prisons. Lancet 1999; 353: 969–973.

    Article  PubMed  CAS  Google Scholar 

  31. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564–581.

    PubMed  CAS  Google Scholar 

  32. Grosset J. Systematic drug susceptibility testing: a necessary component of the ‘DOTS Plus’ strategy? Int J Tuberc Lung Dis 1999; 3: 549–550.

    PubMed  CAS  Google Scholar 

  33. Collins C, Grange J, Yates M. Tuberculosis bacteriology: organization and practice. Reed Elsevier, Boston, 1997.

    Google Scholar 

  34. Vareldzis BP, Grosset J, de Kantor I, et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis 1994; 75: 1–7.

    Article  PubMed  CAS  Google Scholar 

  35. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–532.

    Article  PubMed  CAS  Google Scholar 

  36. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992; 41(RR-11): 59–71.

    Google Scholar 

  37. Rieder HL, Watson JM, Raviglione MC, et al. Surveillance of tuberculosis in Europe. Eur Respir J 1996; 9: 1097–1104.

    Article  PubMed  CAS  Google Scholar 

  38. Rieder HL, International Union Against Tuberculosis and Lung Disease, personal communication, September 1999.

    Google Scholar 

  39. Timperi R, Sloutsky A, Farmer PE. Global laboratory testing capacity for tuberculosis. Int J Tuberc Lung Dis 1998; 2: S290–S291.

    Google Scholar 

  40. Becerra MC, Freeman J, Bayona J, et al. Projections for an urban TB epidemic: The impact of control measures and emerging drug resistance in Lima’s northern shantytowns. In: Becerra MC, Epidemiology of tuberculosis in the northern shantytowns of Lima, Peru. Sc.D. Thesis. Harvard University, Boston, MA, 1999.

    Google Scholar 

  41. Coninx R, Pfyffer GE, Mathieu C, et al. Drug resistant tuberculosis in prisons in Azerbaijan: case study. BMJ 1998; 316: 1423–1425.

    Article  PubMed  CAS  Google Scholar 

  42. Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrugresistant tuberculosis. Int J Tuberc Lung Dis (in press).

    Google Scholar 

  43. UNAIDS, World Health Organization. Access to drugs: UNAIDS technical update. UNAIDS, Geneva, 1998.

    Google Scholar 

  44. Kim JY, Furin JJ, Shakow AD, et al. Treatment of multidrug-resistant tuberculosis (MDR-TB): new strategies for procuring second-and third-line drugs. Int J Tuberc Lung Dis 1999; 3(Suppl. 1): S81.

    Google Scholar 

  45. Rieder HL. Socialization patterns are key to transmission dynamics of tuberculosis. Int J Tuberc Lung Dis 1999; 3: 177–178.

    PubMed  CAS  Google Scholar 

  46. Chaulet P. The supply of antituberculosis drugs: price evolution. Tuber Lung Dis 1995; 76: 261–263.

    Article  PubMed  CAS  Google Scholar 

  47. Quick JD. Managing drug supply: the selection, procurement, distribution, and use of Pharmaceuticals. Second edition. Kumarian Press, West Hartford, CT, 1997.

    Google Scholar 

  48. Chaulet P. The supply of antituberculosis drugs and national drug policies. Tuber Lung Dis 1992; 73: 295–304.

    Article  PubMed  CAS  Google Scholar 

  49. Weil DC. Drug supply: meeting a global need, p. 123–149. In: Porter JDH, McAdam KPWJ (eds.), Tuberculosis: Back to the Future. John Wiley and Sons, Ltd., New York, 1994.

    Google Scholar 

  50. World Health Organization. Tenth HWO model list of essential drugs. World Health Organization, Geneva, 1998.

    Google Scholar 

  51. Raviglione M, World Health Organization, personal communication, September 1999.

    Google Scholar 

  52. Burnett F. Pooled procurement of Pharmaceuticals in the Caribbean. Proceedings from the Caricorn Health Ministers Conference, Trinidad July 15-18, 1996.

    Google Scholar 

  53. Fefer E, Pan American Health Organization, personal communication, May 1999.

    Google Scholar 

  54. Anonymous. Rifampicin or ethambutol in the routine treatment of tuberculosis. BMJ 1973; 4: 56.

    Google Scholar 

  55. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995; 345: 1545–1548.

    Article  PubMed  CAS  Google Scholar 

  56. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can’t afford not to try it. N Engl J Med 1993; 328: 576–578.

    Article  PubMed  CAS  Google Scholar 

  57. Peloquin CA. Controversies in the management of Mycobacterium avium complex infection in AIDS patients. Ann Pharmacother 1993; 27: 928–937.

    PubMed  CAS  Google Scholar 

  58. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996; 77: 37–42.

    Article  PubMed  CAS  Google Scholar 

  59. Patel A, MCKeon J. Avoidance and management of adverse reactions to antituberculous drugs. Drug Safety 1995; 12: 1–25.

    Article  PubMed  CAS  Google Scholar 

  60. Ali J. Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem. Postgrad Med 1996; 99: 217–220, 230-231, 235-236.

    PubMed  CAS  Google Scholar 

  61. Holdiness, MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9: 5115–44.

    Article  Google Scholar 

  62. Gonzalez Montaner LJ, Dambrosi A, et al. Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle 1982; 63: 291–294.

    Article  Google Scholar 

  63. Zierski M, Bek E. Side-effects of drug regimens used in short course chemotherapy for pulmonary tuberculosis: a controlled clinical study. Tubercle 1980; 61: 41–49.

    Article  PubMed  CAS  Google Scholar 

  64. Newton R. Side effects of drugs used to treat tuberculosis. Scott Med J 1975; 20: 47–49.

    PubMed  CAS  Google Scholar 

  65. Perez-Stable E, Hopewell P. Current tuberculosis treatment regimens: choosing the right one for your patient. Clin Chest Med 1989; 10: 323–339.

    PubMed  CAS  Google Scholar 

  66. Nariman S. Advere reactions to the drugs used in the treatment of tuberculosis. Adverse Drug React Acute Poison Rev 1988; 7: 207–227.

    CAS  Google Scholar 

  67. Holdiness MR. Neurological manifestations and toxicities of the antituberculous drugs: a review. Med Toxicol 1987; 2: 33–51.

    PubMed  CAS  Google Scholar 

  68. Yew WW, Wong CF, Wong PC, et al. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after co-administration of cycloserine and Ofloxacin. Clin Infect Dis 1993; 17: 288–289.

    Article  PubMed  CAS  Google Scholar 

  69. Tack KJ, Smith JA. The safety profile of Ofloxacin. Am J Med 1989; 87: 78S–81S.

    PubMed  CAS  Google Scholar 

  70. Akhtar AJ, Crompton GK, Schonell MM. Para-aminosalicylic acid as a cause of intestinal malabsorption. Tubercle 1968; 49: 328–331.

    Article  PubMed  CAS  Google Scholar 

  71. Munkner T. Studies on goitre due to para-aminosalicylic acid. Scand J Repir Dis 1969; 50: 212–226.

    CAS  Google Scholar 

  72. Paaby P, Mnorvin E. The absorption of vitamin B12 during treatment with paraaminosalicylic acid. Acta Med Scand 1966; 180: 561–564.

    Article  PubMed  CAS  Google Scholar 

  73. Levine R. Steatorrhea induced by para-aminosalicylic acid. Ann Intern Med 1968; 68: 1265–1270.

    PubMed  CAS  Google Scholar 

  74. Moore V. A review of side-effects experienced by patients taking clofazimine. Leprosy Rev 1983; 54: 327–335.

    PubMed  CAS  Google Scholar 

  75. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present, and future. Drug Safety 1995; 13: 343–358.

    Article  PubMed  CAS  Google Scholar 

  76. Lietman P. Fluroquinolone toxicities. An update. Drugs 1995; 49(Suppl. 2): 159–163.

    Article  PubMed  CAS  Google Scholar 

  77. Bucco T, Meligrana G, De Luca V. Neurotoxic effects of cycloserince therapy in pulmonary tuberculosis of adolescents and young adults. Scand J Respir Dis 1970; 71(Suppl.): 259–265.

    CAS  Google Scholar 

  78. Helmy B. Side effects of cycloserine. Scand J Respir Dis 1970; 71(Suppl.): 200–205.

    Google Scholar 

  79. Mattie H, Craig W, Pechere J. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrobiol Chemother 1989; 24: 281–293.

    Article  CAS  Google Scholar 

  80. Kahlmeter G, Dahlager J. Aminoglcoside toxicity — a review of clinical studies published between 1975 and 1982. J Antimicrobiol Chemother 1984; 13(Suppl. A): 9–22.

    Article  Google Scholar 

  81. Kropp R, Jungbluth H, Radenbach K. Influence of capreomycin on renal function (preliminary results). Antibiotic Chemother 1970; 16: 59–68.

    CAS  Google Scholar 

  82. Devadatta S, Menon N, Nazareth O, et al. A double-blind study to determine the maximum tolerance dose of ethionamide when administered twice-weekly to patients with pulmonary tuberculosis. Tubercle 1970; 51: 263–269.

    Article  PubMed  CAS  Google Scholar 

  83. Combs DL, O’Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112: 397–406.

    PubMed  CAS  Google Scholar 

  84. Govindaraj M. Multiple-drug reactions to tuberculosis: an illustrative case. Tubercle 1968; 49: 416–418.

    Article  PubMed  CAS  Google Scholar 

  85. Furin JJ, Mitnick CD, Becerra M, et al. Absence of serious adverse effects in a cohort of Peruvian patients receiving community-based treatment for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 1999; 3(Suppl. 1): S81.

    Google Scholar 

  86. Program in Infectious Disease and Social Change. Community-based treatment and control of multidrug-resistant tuberculosis: A DOTS-Plus handbook. Program in Infectious Disease and Social Change, Harvard Medical School, Boston, MA, 1999.

    Google Scholar 

  87. Quillian J. Community health workers and primary health care in Honduras. J Am Acad Nurse Pract 1993; 5: 219–225.

    Article  PubMed  CAS  Google Scholar 

  88. Ramprasad V. Community health workers—and evolving force. World Health Forum 1988; 9: 229–234.

    PubMed  CAS  Google Scholar 

  89. Freeman P. A culturally oriented curriculum for aboriginal health workers. World Health Forum 1993; 14: 262–266.

    PubMed  CAS  Google Scholar 

  90. Ronsmans C, Bennish M, Wierzba T. Diagnosis and management of dysentery by community health workers. Lancet 1998; 2: 552–555.

    Google Scholar 

  91. Christensen P, Karlqvst S. Community health workers in a Peruvian slum area: an evaluation of their impact on health behavior. Bull Pan Am Health Organ 1990; 24: 183–196.

    PubMed  CAS  Google Scholar 

  92. Ghebreyesus T, Alemayehu T, Bosman A, et al. Community participation in malaria control in Tigray region Ethiopia. Acta Trop 1996; 61: 145–156.

    Article  PubMed  CAS  Google Scholar 

  93. Mburu F. Whither community health workers in the age of structural adjustment?. Soc Sci Med 1994; 39: 883–885.

    Article  PubMed  CAS  Google Scholar 

  94. Rifkin S. Paradigms lost: toward a new understanding of community participation in health programs. Acta Trop 1996; 61: 79–92.

    Article  PubMed  CAS  Google Scholar 

  95. McCord C, Kleinman A. A successful program for para-professionals treating childhood diarrhea and pneumonia. Trop Doctor 1978; 8: 220–225.

    CAS  Google Scholar 

  96. Zeitz PS, Harrison LM, Lopez M, Cornale G. Community health worker competency in managing acute respiratory infections of childhood in Bolivia. Bull Pan Am Health Organ 1993; 27: 109–119.

    PubMed  CAS  Google Scholar 

  97. Farmer PE, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and “compliance”: lessons from rural Haiti. Semin Respir Infect 1991; 6: 373–379.

    Google Scholar 

  98. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to shortcourse chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423–430.

    PubMed  CAS  Google Scholar 

  99. Mitnick CD, Freeman J, Bayona J, et al. Amplification of drug resistance by standardized short-course chemotherapy. Working Paper No. 7, Boston, MA: Program in Infectious Disease and Social Change, 1999.

    Google Scholar 

  100. Mirzoyev F, Leclerc A. Modification of resistance profiles to first line drugs among patients under standard, DOTS based treatment protocol. Int J Tuberc Lung Dis 1999; 3(Suppl. 1): S123.

    Google Scholar 

  101. Matthys F. Treatment failure in Colony 33: causes for concern. Presentation at the 30th IUATLD World Conference on Lung Health, Madrid, Spain, September 14-18, 1999.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Program in Infectious Disease and Social Change, Harvard Medical School, Boston, MA, USA

    Paul E. Farmer, Sonya S. Shin, Jaime Bayona, Jim Y. Kim, Jennifer J. Furin & Joel G. Brenner

Authors
  1. Paul E. Farmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonya S. Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaime Bayona
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jim Y. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer J. Furin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joel G. Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mycobacterium Reference Laboratory, Institute of Medical & Veterinary Science, Adelaide, Australia

    Ivan Bastian

  2. Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium

    Françoise Portaels

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Farmer, P.E., Shin, S.S., Bayona, J., Kim, J.Y., Furin, J.J., Brenner, J.G. (2000). Making DOTS-Plus work. In: Bastian, I., Portaels, F. (eds) Multidrug-resistant Tuberculosis. Resurgent and Emerging Infectious Diseases, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4084-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4084-3_19

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5794-3

  • Online ISBN: 978-94-011-4084-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation